中华实验外科杂志
中華實驗外科雜誌
중화실험외과잡지
CHINESE JOURNAL OF EXPERIMENTAL SURGERY
2012年
8期
1506-1508
,共3页
黄伟%邓波%王如文%蒋耀光%谭群友%范小清
黃偉%鄧波%王如文%蔣耀光%譚群友%範小清
황위%산파%왕여문%장요광%담군우%범소청
乳腺癌抗雌激素药物耐药蛋白1%食管鳞癌%组织芯片
乳腺癌抗雌激素藥物耐藥蛋白1%食管鱗癌%組織芯片
유선암항자격소약물내약단백1%식관린암%조직심편
Breast cancer anti-estrogen drug resistance protein 1%Esophageal squamous cell carcinoma%Tissue microassay
目的 探讨乳腺癌抗雌激素药物耐药蛋白1( BCAR1)在食管鳞癌血清和组织中的表达及临床意义.方法 采用酶联免疫吸附试验(ELISA)检测2010年2月至2011年1月间46例食管鳞癌患者和25例正常人血清BCAR1水平;应用组织芯片和免疫组织化学方法检测2004年2月至2006年7月间106例食管鳞癌和癌旁正常组织中BCAR1表达.结果 食管鳞癌组BCAR1血清水平显著高于正常对照组(P<0.01);晚期食管鳞癌BCAR1血清水平显著高于早期食管鳞癌组和正常对照组(P<0.01);切除肿瘤后,血清BCAR1水平有逐渐下降趋势.BCAR1蛋白在食管鳞癌组织中阳性率为97%( 103/106),癌旁正常食管组织中有16例弱阳性,阳性率为15% (16/106),两者差异有统计学意义(P<0.01);BCAR1阳性表达与食管鳞癌的分化明显相关(P<0.05),与年龄、性别、淋巴结转移、浸润深度和TNM分期明显无关(P>0.05).生存分析提示BCAR1高表达组生存时间少于低表达组(P<0.01);经COX模型多因素生存分析,显示BCAR1表达和淋巴结转移为独立预后因素.结论 食管鳞癌血清和组织中BCAR1水平显著高于正常对照组,并与疾病进展、治疗效果、分化程度和预后相关,可作为食管鳞癌诊断和判断预后重要新的肿瘤分子标记.
目的 探討乳腺癌抗雌激素藥物耐藥蛋白1( BCAR1)在食管鱗癌血清和組織中的錶達及臨床意義.方法 採用酶聯免疫吸附試驗(ELISA)檢測2010年2月至2011年1月間46例食管鱗癌患者和25例正常人血清BCAR1水平;應用組織芯片和免疫組織化學方法檢測2004年2月至2006年7月間106例食管鱗癌和癌徬正常組織中BCAR1錶達.結果 食管鱗癌組BCAR1血清水平顯著高于正常對照組(P<0.01);晚期食管鱗癌BCAR1血清水平顯著高于早期食管鱗癌組和正常對照組(P<0.01);切除腫瘤後,血清BCAR1水平有逐漸下降趨勢.BCAR1蛋白在食管鱗癌組織中暘性率為97%( 103/106),癌徬正常食管組織中有16例弱暘性,暘性率為15% (16/106),兩者差異有統計學意義(P<0.01);BCAR1暘性錶達與食管鱗癌的分化明顯相關(P<0.05),與年齡、性彆、淋巴結轉移、浸潤深度和TNM分期明顯無關(P>0.05).生存分析提示BCAR1高錶達組生存時間少于低錶達組(P<0.01);經COX模型多因素生存分析,顯示BCAR1錶達和淋巴結轉移為獨立預後因素.結論 食管鱗癌血清和組織中BCAR1水平顯著高于正常對照組,併與疾病進展、治療效果、分化程度和預後相關,可作為食管鱗癌診斷和判斷預後重要新的腫瘤分子標記.
목적 탐토유선암항자격소약물내약단백1( BCAR1)재식관린암혈청화조직중적표체급림상의의.방법 채용매련면역흡부시험(ELISA)검측2010년2월지2011년1월간46례식관린암환자화25례정상인혈청BCAR1수평;응용조직심편화면역조직화학방법검측2004년2월지2006년7월간106례식관린암화암방정상조직중BCAR1표체.결과 식관린암조BCAR1혈청수평현저고우정상대조조(P<0.01);만기식관린암BCAR1혈청수평현저고우조기식관린암조화정상대조조(P<0.01);절제종류후,혈청BCAR1수평유축점하강추세.BCAR1단백재식관린암조직중양성솔위97%( 103/106),암방정상식관조직중유16례약양성,양성솔위15% (16/106),량자차이유통계학의의(P<0.01);BCAR1양성표체여식관린암적분화명현상관(P<0.05),여년령、성별、림파결전이、침윤심도화TNM분기명현무관(P>0.05).생존분석제시BCAR1고표체조생존시간소우저표체조(P<0.01);경COX모형다인소생존분석,현시BCAR1표체화림파결전이위독립예후인소.결론 식관린암혈청화조직중BCAR1수평현저고우정상대조조,병여질병진전、치료효과、분화정도화예후상관,가작위식관린암진단화판단예후중요신적종류분자표기.
Objective To determine clinical significance of breast eancer anti-estrogen drug resistance protein 1 (BCAR1) expression in sera and tissues of esophageal squamous cell cancer (ESCC).Methods Between Feb.2010 and Jan.2011,serum BCAR1 levels in 46 cases of ESCC and 25 healthy volunteers from our department were detected by using enzyme linked immunosorbent assay (ELISA).A total of 106 ESCC samples and their adjacent normal tissues from our department obtained between Feb.2004 and July 2006 were investigated for BCAR1 protein expression by using tissue microassay (TMA) and immunohistochemistry (IHC).Results The serum BCAR1 levels were significantly higher in ESCC group than in normal control group (P <0.01 ).The serum BCAR1 levels in advanced ESCC group were significantly higher than in early ESCC group and normal control group ( P < 0.01 ).The serum BCAR1 levels were decreased after removal of ESCC. BCAR1 protein was strongly expressed in 97% of ESCC samples ( 103/106),while weekly expressed in 15% of adjacent normal tissues (16/106) ( P < 0.001 ).There was a significant correlation between BCAR1 positive expression and differentiation (P <0.05 ),however,there was no correlation between BCAR1 positive expression and age,gender,lymph node metastasis,depth of invasion and TNM stage ( P > 0.05 ).Survival analysis revealed that BCAR1 low expression was in favor of survival time in comparison with BCAR1 high expression ( P < 0.01 ). BCAR1 expression and lymph node metastasis were independent prognosis indictor by COX regression analysis.Conclusion BCAR1 protein expression is significantly higher in sera and tissues of ESCC than normal control group,and has a correlation with progression,therapeutic efficacy,differentiation and prognosis of ESCC.BCAR1 protein might be used as a new tumor marker for diagnosis and prognosis of ESCC.